132 related articles for article (PubMed ID: 21258118)
1. Metabolic modulation in heart failure: high time for a definitive clinical trial.
Ashrafian H; Neubauer S
Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
[No Abstract] [Full Text] [Related]
2. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Gao D; Ning N; Niu X; Hao G; Meng Z
Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulation as a target for heart failure treatment: current perspective.
Chenniapan S; Manchanda SC
Indian Heart J; 2007; 59(4):370-4. PubMed ID: 19126947
[No Abstract] [Full Text] [Related]
4. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
5. Metabolic therapy for heart failure.
Essop MF; Opie LH
Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
[No Abstract] [Full Text] [Related]
6. Trimetazidine and cardioprotection: facts and perspectives.
Tsioufis K; Andrikopoulos G; Manolis A
Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
[TBL] [Abstract][Full Text] [Related]
7. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
[TBL] [Abstract][Full Text] [Related]
8. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
Jackson G
Int J Clin Pract; 2006 Aug; 60(8):891-2. PubMed ID: 16893429
[No Abstract] [Full Text] [Related]
9. Trimetazidine: the future of cardiac function?
Di Napoli P; Taccardi AA
Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
[No Abstract] [Full Text] [Related]
10. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
11. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
O'Meara E; McMurray JJ
Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
[TBL] [Abstract][Full Text] [Related]
12. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
13. Metabolic support for the heart: complementary therapy for heart failure?
Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
[TBL] [Abstract][Full Text] [Related]
14. [Metabolic therapy for heart failure].
Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
[TBL] [Abstract][Full Text] [Related]
15. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
[TBL] [Abstract][Full Text] [Related]
16. [Plasma hemostasis and biochemical indices in trimetazidine treatment of patients with chronic heart failure].
Tereshchenko SN; Drozdov VN; Levchuk NN; Demidova IV
Ter Arkh; 1998; 70(6):41-4. PubMed ID: 9695225
[TBL] [Abstract][Full Text] [Related]
17. [Trimetazidine in the Treatment of Chronic HeartFailure].
Zhirov IV; Osmolovskaya YF; Tereshchenko SN
Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737
[TBL] [Abstract][Full Text] [Related]
18. Can metabolic manipulation reverse myocardial dysfunction?
Cokkinos DV
Eur Heart J; 2001 Dec; 22(23):2138-9. PubMed ID: 11913472
[No Abstract] [Full Text] [Related]
19. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects.
Pascale C; Fornengo P; Epifani G; Bosio A; Giacometto F
Lancet; 2002 Mar; 359(9312):1153-4. PubMed ID: 11943290
[No Abstract] [Full Text] [Related]
20. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover?
Tabbi-Anneni I; Helies-Toussaint C; Morin D; Bescond-Jacquet A; Lucien A; Grynberg A
J Pharmacol Exp Ther; 2003 Mar; 304(3):1003-9. PubMed ID: 12604675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
